Document is current
Any future updates will be listed below
-
Authors
Maher, Keri R.
Shafer, Danielle
Schaar, Dale
Bandyopadhyay, Dipankar
Deng, Xiaoyan
Wright, John
Piekarz, Richard
Rudek, Michelle A.
Harvey, R. Donald
Grant, Steven
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03772925 at ClinicalTrials.govDocuments that mention this clinical trial
A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome
https://doi.org/10.1007/s00280-024-04742-9
Pevonedistat plus belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome: A phase I multicenter study.
https://doi.org/10.1200/jco.2023.41.16_suppl.e19015
-
Funding
Funding for this research was provided by:
Winn Career Development Award
NIH-NCI Cancer Center Support Grant (P30 CA016059, P30 CA016059, P30 CA016059, P30 CA016059)
NIH: ETCTN (UM1CA186644, UM1CA186644, UM1CA186644, UM1CA186644, UM1CA186644, UM1CA186644)
NIH (P30CA006973, P30CA006973)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Shared Instrument Grant (S10OD020091)
National Center for Advancing Translational Sciences (UL1TR003098)
Leukemia and Lymphoma Society (R6508-18)
- License Information
-
More Information
Article History
Received: 9 August 2024
Accepted: 9 December 2024
First Online: 17 January 2025
Declarations
:
: The authors declare no competing interests.
: NCI Central IRB served as the IRB or Record for this study. All patients provided signed informed consent prior to participation in this study.
